| Ms Dani Perry, CF-SLP | |
|
1597 Avenue D, Suite 4, Billings, MT 59102-3010 | |
| (970) 985-8372 | |
| Not Available |
| Full Name | Ms Dani Perry |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1597 Avenue D, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316394497 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Dani Perry, CF-SLP 51 Sage Bloom Ct, Unit D, Bozeman, MT 59718-8631 Ph: (970) 985-8372 | Ms Dani Perry, CF-SLP 1597 Avenue D, Suite 4, Billings, MT 59102-3010 Ph: (970) 985-8372 |
News Archive
A new treatment is the first to target the underlying genetic cause of AMD, which affects more than 600,000 people in the UK alone.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.
CMU's Jeffrey O. Hollinger, director of the center, and Professor Krzysztof Matyjaszewski have received a three-year, $2.9 million U.S. Department of Defense research grant to develop a therapy that would aid amputees, specifically wounded soldiers. The therapy aims to prevent bone nodules from forming in the muscle at the site of amputation, a painful condition that makes it difficult for amputees to wear limb prostheses.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
› Verified 9 days ago
Mrs. Brooke Leigh Oftedal, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1750 Morocco Dr, Billings, MT 59105 Phone: 406-671-1854 | |
Jessica Potter, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1597 Avenue D Ste 4, Billings, MT 59102 Phone: 406-690-6996 | |
Kathryn Marie Satterfield, MCSDCCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3940 Rimrock Rd, Billings, MT 59102 Phone: 406-655-5658 Fax: 406-655-5639 | |
Emily Berendts Anderson, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Latisha Lee Montgomery, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-7166 | |
Rock Creek Teletherapy, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1302 24th St W, Suite 132, Billings, MT 59102 Phone: 888-241-4332 Fax: 406-794-0454 | |
Kelly Marie Geary Ruggles, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 708 Broadwater Ave, Billings, MT 59101 Phone: 406-259-1680 Fax: 406-259-1777 |